Cellectis (NASDAQ: CLLS) schedules June 25, 2026 annual meeting in Paris
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Cellectis S.A. has scheduled its annual shareholders general meeting for June 25, 2026 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. The formal notice and related meeting information are available on the company’s investor website.
Positive
- None.
Negative
- None.
Key Figures
Meeting date: June 25, 2026
Meeting time: 2:30 p.m. CET
Meeting venue: Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris
+1 more
4 metrics
Meeting date
June 25, 2026
Annual shareholders general meeting
Meeting time
2:30 p.m. CET
Annual shareholders general meeting
Meeting venue
Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris
Location of 2026 annual shareholders meeting
Headquarters location
Paris, France
Corporate headquarters of Cellectis
Key Terms
Form 6-K, foreign private issuer, annual general meeting, gene-editing platform, +2 more
6 terms
Form 6-K regulatory
"Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"
A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.
foreign private issuer regulatory
"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
annual general meeting financial
"Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026"
gene-editing platform technical
"using its pioneering gene-editing platform to develop life-saving cell and gene therapies"
CAR T immunotherapies technical
"an allogeneic approach for CAR T immunotherapies in oncology"
allogeneic approach technical
"The company utilizes an allogeneic approach for CAR T immunotherapies"
FAQ
Where will the Cellectis (CLLS) 2026 annual general meeting take place?
The 2026 annual general meeting will be held at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. This physical location is specified in the company’s announcement for shareholders planning to attend in person.
What type of company is Cellectis (CLLS)?
Cellectis is a clinical-stage biotechnology company focused on gene editing to develop cell and gene therapies. It uses an allogeneic, or off-the-shelf, approach for CAR T immunotherapies in oncology and gene therapies for other indications, supported by in-house manufacturing capabilities.
How can investors contact Cellectis investor relations about the meeting?
Investors can contact Cellectis investor relations by emailing investors@cellectis.com, addressed to Arthur Stril, Chief Financial Officer and Chief Business Officer. This contact is provided for questions related to the company, including those concerning the annual general meeting arrangements.